

PROGRAMME



Biofit

FOSTERING
INNOVATION
& TRANSFER

The leading European partnering event
for early-stage deals and investment
rounds in the Life Sciences field



NEW DESTINATION

MARSEILLE

FRANCE

8th edition

DECEMBER
10 & 11
2 0 1 9

www.biofit-event.com

 @BIOFIT_EVENT

BIOFIT AT A GLANCE

BioFIT is both the leading partnering event in Europe for technology transfer, academia-industry collaborations, early-stage innovation deals and the European marketplace for pre-seed, seed and Series A investment rounds in the **Life Sciences** field.



WHO WILL YOU MEET?



STEERING COMMITTEE

PHARMA, BIOTECH

- Maria Bobadilla**
SENIOR DIRECTOR, EXTENDING INNOVATION NETWORK, **ROCHE** 🇫🇷
- Adrian Carter**
CORPORATE VICE PRESIDENT AND GLOBAL HEAD OF DISCOVERY RESEARCH COORDINATION, **BOEHRINGER INGELHEIM** 🇩🇪
- Sami Chtourou**
EXECUTIVE VICE PRESIDENT INNOVATION & SCIENTIFIC AFFAIRS, **LFB** 🇫🇷
- Florence Dal Degan**
R&D INNOVATION SOURCING DIRECTOR, **NOVO NORDISK** 🇩🇪
- Guy Hélin**
CEO, **SYNGULON** 🇫🇷
- Stephan Lensky**
CHIEF OPERATING AND CHIEF BUSINESS OFFICE, **EPIMAB BIOTHERAPEUTICS** 🇫🇷
- Sabrina Lesage**
STRATEGIC ALLIANCES MANAGER, **PFIZER** 🇫🇷
- Sara Nunez-Garcia**
SENIOR DIRECTOR, **ROIVANT SCIENCES** 🇫🇷
- Marie-Ange N'Zoutani**
DIRECTOR, EXTERNAL INNOVATION DRUG DISCOVERY, BUSINESS DEVELOPMENT & LICENSING, **SANOFI** 🇫🇷
- Frédéric Scaërou**
SENIOR DIRECTOR, HEAD OF EXTERNAL INNOVATION EUROPE AND ASIA, **IPSEN INNOVATION** 🇫🇷
- Joachim Vogt**
DIRECTOR, SEARCH AND EVALUATION, WESTERN EUROPE, **ABBVIE** 🇩🇪
- Nadine Weisslinger-Darmon**
MEDICAL DIRECTOR SPECIALTY PRODUCTS, CLINICAL RESEARCH AND ACADEMIC ALLIANCES, **GSK** 🇫🇷

ACADEMIA, TTOs

- Hervé Ansanay**
OPERATIONS DIRECTOR, **SATT AXLR** 🇫🇷
- Jürgen Bauer**
DEPUTY MANAGING DIRECTOR, **EMBLEM TECHNOLOGY TRANSFER** 🇩🇪
- Garold Breit**
CEO, **BREIT IDEAS LLP** 🇫🇷
- Jean-Luc Chagnaud**
HEALTHCARE BUSINESS DEVELOPMENT MANAGER & INTELLECTUAL PROPERTY MANAGER, **AQUITAINE SCIENCE TRANSFERT** 🇫🇷
- Anthony Daccache**
BUSINESS DEVELOPER, **SATT NORD** 🇫🇷
- Caroline Dreyer**
PRESIDENT, **SATT CONECTUS** 🇫🇷
- Lilla Farkas**
HEAD, OFFICE OF THE MANAGING DIRECTOR, RESEARCH COORDINATOR, **MPI-CBG, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS** 🇩🇪
- Esther Lange**
INDUSTRY LIAISON MANAGER, **ASCENION** 🇩🇪

ASSOCIATIONS, CLUSTERS

- Nicolas Carboni**
PRESIDENT, **RÉSEAU C.U.R.I.E.** 🇫🇷
- Barbara Freischem**
MANAGING DIRECTOR, **EBE - EUROPEAN BIOPHARMACEUTICAL ENTERPRISES** 🇩🇪
- Yohan Grosjean**
COMMUNICATION OFFICER, **AFSSI - THE FRENCH ASSOCIATION OF OUTSOURCING AND INNOVATIVE COMPANIES** 🇫🇷
- Jean-Louis Hunault**
PRESIDENT, **SIMV - THE FRENCH ASSOCIATION OF THE ANIMAL HEALTH INDUSTRY** 🇫🇷
- Marco Pintore**
GENERAL MANAGER, **BIOVALLEY FRANCE** 🇫🇷
- Christian Policard**
MEMBER OF THE BOARD, CHAIRMAN OF THE BUSINESS DEVELOPMENT SUB-COMMITTEE, **FRANCE BIOTECH** 🇫🇷
- Emilie Royere**
GENERAL MANAGER, **EUROBIOMED** 🇫🇷
- Etienne Vervaecke**
GENERAL MANAGER, **EURASANTÉ & CLUBSTER-NHL** 🇫🇷

INVESTORS

- Anta Gkelou**
ANALYST, **SOFINNOVA PARTNERS** 🇫🇷
- Frank Hensel**
PRINCIPAL, **HIGH-TECH GRÜNDERFONDS** 🇩🇪
- Jérôme Majoie**
GENERAL MANAGER, **FOUNDATION FOURNIER-MAJOIE** 🇫🇷
- Daniel Parera**
EXECUTIVE IN RESIDENCE, **TVM CAPITAL GMBH** 🇩🇪
- Lotfi Yelles Chaouche**
PARTNER, **THEODORUS FUND** 🇫🇷

THEY TRUST US

PHARMA

AbbVie | Bayer Healthcare | Boehringer Ingelheim
| GSK | J&J Innovation | Lilly | Merck | MSD |
Novo Nordisk | Pfizer | Roche | Sanofi | Santen |
Sumitomo Dainippon Pharma...

VETERINARY

Bayer Animal Health | Boehringer Ingelheim Animal
Health | Ceva Animal Health | MSD Animal Health |
Vetoquinol | Virbac | Zoetis...

BIOTECH

Biogazelle | Genfit | LFB | LNC Therapeutics | Oxurion
(former ThromboGenics) | Syngulon | TiGenix...

TTOs AND ACADEMIA

Ascenion | CNRS | EMBLEM | Imperial Innovations
| INRA | LifeArc | Max Planck Institute | NIH |
Princeton University | University of Birmingham...

INVESTORS

(PRE-SEED, SEED, SERIES A)

Andera Partners | Fund+ | Gimv | High-Tech
Gründerfonds | Julz Co | Medicxi | MS Ventures |
Sofinnova Partners | Truffle Capital | TVM Capital...

SPONSORS

GOLD SPONSORS



SANOFI

SILVER SPONSORS



MSD

INVENTING FOR LIFE



MSD

Animal Health

BRONZE SPONSORS



Boehringer
Ingelheim



evotec



novo nordisk®



CONTRIBUTING SPONSORS

Advent
France Biotechnology



innate pharma



PARTNERING

48 hours to meet your future project partners, obtain funding and accelerate innovation

- 1** **LOG IN** to the partnering platform and **IDENTIFY** today's innovative products, technologies, licensing opportunities as well as potential project partners.
- 2** **REQUEST** and **PRE-SCHEDULE** one-to-one meetings with the most qualified players in the Life Sciences field.
- 3** **MEET** your future partners and **DEVELOP** new collaboration and partnerships.



WOULD-BE CEO

Are you a bioentrepreneur seeking a project? Or do you have projects needing a CEO?

As talented CEOs are frequently sought-after by many actors of the biotech industry, this Would-be CEO session will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this important issue.

Any bioentrepreneur looking for a project to get involved in is welcome to join BioFIT and particularly the Would-be CEO session. Any incubator, tech transfer entity or scientific founder looking for an entrepreneur to lead their start-up projects is also welcome to join.

Bioentrepreneurs workshop:

- Panorama of European entrepreneurial training programmes
- How do I find the right co-founders? Which networks to activate? How do we find the risk takers and the co-entrepreneurs? Hear from savvy entrepreneurs and investors to receive feedback and best practices.

Networking cocktail:

This networking moment will be the occasion to establish collaborations between future entrepreneurs and projects in need of CEOs.

PITCH SESSIONS

The early-stage innovations you need

The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects, licensing opportunities and services in order to foster partnerships and business development in the Life Sciences field.

START-UP SLAMS

The Start-up Slams are a great opportunity for **young companies** (and particularly start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors.

Pitch fees: Free for all BioFIT registrants.

Sponsored by:



COLLABORATIVE AND LICENSING OPPORTUNITY PRESENTATIONS

The Collaborative and Licensing Opportunity Presentations are a great opportunity for **TTOs, universities, research institutes and companies** to showcase their early-stage technologies in front of potential partners, in order to entail a collaborative project and/or a licensing deal.

Pitch fees: Free for all BioFIT registrants.

SERVICE PRESENTATIONS

The Service Presentations are a great opportunity for **service providers and technology platforms with an innovative offer** to showcase their offers in front of potential clients.

Pitch fees: From €200 to €350 additional fees to the registration fees if selected.

HOW DOES IT WORK?



DAY ONE

TUESDAY, DECEMBER 10TH

	Conferences and roundtable discussions	Pitch sessions	Partnering
7.30 am 9.00 am	NAME BADGE PICKUP & WELCOME COFFEE		
9.00 am 10.30 am	Working with corporate venture funds	What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?	Collaborative and Licensing Opportunity Presentations
			One-to-one meetings
10.30 am 11.00 am	☕ NETWORKING BREAK		
11.00 am 12.30 pm	PLENARY SESSION What is pharma looking for nowadays?		
12.30 pm 2.00 pm	✂ LUNCH		
2.00 pm 3.00 pm	What are the milestones to be reached for an academic asset?	Managing pre-competitive collaboration in Life Sciences	Start-up Slams
3.15 pm 4.15 pm	How can big data fuel collaborations between industry and academic institutions?	Which funding models to accelerate anti-parasitic and anti-infectious innovation?	
			One-to-one meetings
4.15 pm 4.45 pm	☕ NETWORKING BREAK		
4.45 pm 6.15 pm	Challenging conventional wisdom: Is early-stage capital as satisfyingly available in Europe as we like to believe?	How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?	Sponsor Presentations
6.30 pm	🍷 BIOPARTY		

DAY TWO

WEDNESDAY, DECEMBER 11TH

	Conferences and roundtable discussions	Pitch Sessions	Partnering
7.30 am 9.00 am	WELCOME COFFEE		
9.00 am 10.00 am	How to prepare your package for a due diligence by a pharma player?	What are the recent successful industry-academia collaborations in Artificial Intelligence?	Service Presentations
10.00 am 10.30 am	☕ NETWORKING BREAK		
10.30 am 11.30 am	How to shape the corporate governance of biotech start-ups at their very first steps to make them successful?		Collaborative and Licensing Opportunity Presentations
11.45 am 12.45 pm	Which new forms of academia-industry partnerships to better mature assets?	Would-be CEO Workshop	One-to-one meetings
12.45 pm 2.00 pm	✂ LUNCH		
2.00 pm 3.30 pm	What's hot, what's not? What's on the investors' wishlist for 2020?	Which promises to be delivered by high potential vaccines?	Start-up Slams
3.30 pm 4.00 pm	☕ NETWORKING BREAK		
4.00 pm 5.30 pm	What to ensure before the creation of a viable spinout opportunity?		Award Ceremony

TRACK 1
Best practices in academia-industry R&D collaborations

TRACK 2:
Nurturing and licensing early-stage assets

TRACK 3:
From pre-seed to Series A: Accessing early-stage investment

ANIMAL HEALTH

CONFERENCE PROGRAMME

1 TRACK

Best practices in academia- industry R&D collaborations

2 TRACK

Nurturing and licensing early-stage assets

3 TRACK

From pre-seed to Series A: Accessing early-stage investment

PLENARY SESSION

WHAT IS PHARMA LOOKING FOR NOWADAYS?

A lot of pharma companies declare that they no longer want to be purely developers of drugs, and thus they progressively transition to become healthcare solution providers, trying to seek broader solutions to answer the patient needs, and changing the way they look at assets: What does it mean for the industry in terms of orientation of their scouting efforts, particularly for early-stage assets?

This session aims to understand pharma's viewpoint, the consequences for the orientation of deals, the way it is going to influence the relationships with academia and biotech start-ups. How does this strategic intention modify the type and the nature of deals that pharma have with start-ups & academic institutions? How is it affecting early-stage licensing deals?

1 TRACK

Best practices in academia- industry R&D collaborations

WHAT ARE THE OUTCOMES OF LONG-LASTING COMMITMENT BETWEEN UNIVERSITIES AND PHARMACEUTICAL COMPANIES?

To which needs do these numerous collaboration schemes answer? What are the specificities of these agreements in terms of management models and R&D means mutualisation? Are short-term reports and industry constraints coherent with multi-years academic agreements?

HOW CAN BIG DATA FUEL COLLABORATIONS BETWEEN INDUSTRY AND ACADEMIC INSTITUTIONS?

How can consolidating and mutualising data between industrial and academic players unlock the full potential of these partnerships? How can we make these data available to pharma and how can we make use of big data to fuel the pharma pipeline? Which collaboration models have emerged around big data? How is the central status of big data already entailing academia-industry collaborations?

WHAT ARE THE RECENT SUCCESSFUL INDUSTRY-ACADEMIA COLLABORATIONS IN ARTIFICIAL INTELLIGENCE?

What are the good examples of partnerships in this field? How have they proved to be fertile in innovation for the benefit of both parties?

MANAGING PRE-COMPETITIVE COLLABORATION IN LIFE SCIENCES: TESTIMONIALS ON OUTCOMES & LIMITS OF EUROPEAN CONSORTIA.

Which research topics are considered good candidates for competitive consortia at the time of precision medicine? Are the current collaborative models (IMI, H2020...) adapted to the research needs? How to balance each party's interests and define the domain of precompetitive research. How can IP problematics be managed??

2 TRACK

Nurturing and licensing early-stage assets

WHAT ARE THE MILESTONES TO BE REACHED FOR AN ACADEMIC ASSET?

How to value an early-stage though promising asset? To what extent do experimented actors help the bio-entrepreneur to aim for a realistic maturation and validation roadmap? How do they help the managing team to understand value inflection points? How do the industry players (pharma, biotech, VC) handle this issue of granting of value to those assets? How could industrial players help academic institutions and TTOs avoid making mistakes at the very early development stages?

HOW TO PREPARE YOUR PACKAGE FOR A DUE DILIGENCE BY A PHARMA PLAYER?

What are the key questions an academic project should address to ensure a valuable licensing deal in the view of pharmaceutical industries? How can a biotech company prepare for a due diligence by big pharma? Which areas are usually underestimated when preparing for a due diligence? What is an efficient due diligence plan? How to prepare an attractive asset to pharma and investors? What are the fundamentals of Due diligence? What are the legal aspects to get prepared to?

WHICH NEW FORMS OF ACADEMIA-INDUSTRY PARTNERSHIPS TO BETTER MATURE ASSETS?

Numerous tools have been created in the last years, how do these early-stage financing vehicles work? On which bases do they ground funds allocation? What are the expectations of the limited partners? Who are the players involved in such investment tools, and what do they await from their involvement in such early-stage funding and investment tools?

WHAT TO ENSURE BEFORE THE CREATION OF A VIABLE SPINOUT OPPORTUNITY?

What does viable mean for TTOs, and do we have the same definition everywhere? On which grounds are TTOs advising to create a spin-off rather than out-licensing the IP or a contract-based R&D collaboration? Which are the benefits, limits, constraints and indication of the spin-out model? What are the key factors to create a well-conceived spin-off company, how to exploit and maximise the value creation?

3 TRACK

From pre-seed to Series A: Accessing early-stage investment

WORKING WITH CORPORATE VENTURE FUNDS

What are the benefits or constraints to go to a corporate venture tool? Is it better to go with a pharma player that wants to be a limited partner in existing funds rather than corporate ventures? As both have fundamentally different missions, what are the validating and limitation effects of working with a corporate VC? How to balance these two effects?

WHICH FUNDING MODELS TO ACCELERATE ANTI-PARASITIC AND ANTI-INFECTIOUS INNOVATION?

Which funding to support new vaccines, drugs and treatment strategies in Africa? What is the role of philanthropic funding? How can foundations and governments form alliances to fund better R&D?

CHALLENGING CONVENTIONAL WISDOM: IS EARLY-STAGE CAPITAL AS SATISFYINGLY AVAILABLE IN EUROPE AS WE LIKE TO BELIEVE?

How is it crucial to question the accepted common idea that Europe only lacks bigger funds for bigger roundtables and for more mature companies? Compared to European later-stage investment markets which are positively underfunded, it seems at first glance that the early-stage capital market is healthy and well-fuelled, but is it genuinely the case? Is the European early-stage capital market as rich in players and capital as it is said to be?

WHAT'S HOT, WHAT'S NOT? WHAT'S ON THE INVESTORS' WISHLIST FOR 2020?

How do the deals and lessons-learned from 2019 investment let us peak at what can be expected for 2020? What are the tips for success for next year? Which therapeutic area will gain or reinforce interest from the VCs? How can you make sure that your business will be on VC's radar?

HOW TO SHAPE THE CORPORATE GOVERNANCE OF BIOTECH START-UPS AT THEIR VERY FIRST STEPS TO MAKE THEM SUCCESSFUL?

Beyond that the sole CEO appointment, how to cope with a pre-established governance from an academic spin-off? How can clashes of culture between researchers and industrials be beneficial and craft a balanced managing team? How are VCs expressing their demands and expectations and how are they filled up? To what extent is leaning on international strategic and scientific committees as soon as they are born a recipe of success?

SPEAKERS

Over 80 international speakers will share their vision and experience. Among them:

Sascha Bucher

Head of Global Transactions and
Head Roivant Basel Pharma
Roivant Sciences Inc. 🇨🇦

Hans Constandt

CEO
ONTOFORCE 🇧🇪

Nicolas Creff

Senior Manager Research
partnerships
EFPIA 🇫🇷

Klaus Dembowsky

CEO
amcure 🇺🇸

Rémi Droller

Managing Partner
Kurma Partners 🇫🇷

Lucie Ellis

Executive Editor
In Vivo – Pharma
Intelligence 🇬🇧

James Eshelby

Executive Director & Head of
Pfizer's Innovative Medicines
Initiative (IMI) Office, External
Science & Innovation
Pfizer 🇺🇸

Pauline Ezanno

Researcher
French National Institute for
Agricultural Research 🇫🇷

Yann Ferrisse

Business Development, Head
Global Antibiotic Research &
Development Partnership 🇨🇦

Tim Haines

Managing Partner
Abingworth 🇬🇧

Atsushi Hinohara

Director Business Development
Division
Kyowa Kirin Pharmaceutical
Research 🇯🇵

Santiago Ini

Director of Business Development
T3-Technion Technology Transfer 🇮🇱

Kevin Johnson

Partner
Medicxi Ventures 🇨🇦

Louise Jonshammar

Attorney at law
AWA 🇸🇪

Christopher Keely

Senior Business Development
Manager
Trinity College Dublin 🇮🇪

Jochen Maas

General Manager, R&D Germany
SANOFI-AVENTIS 🇩🇪

João Ribas

Associate
Novo Seeds 🇵🇹

SPEAKERS

Sabine Riffault

Director of research
French National Institute for
Agricultural Research 🇫🇷

Sylvain Sachot

Investment Director
Asabys Partner 🇫🇷

Meriem Sefta

Head of Partnerships
Owkin 🇫🇷

Benjamin Soffer

Head of Strategic Corporate
Partnerships
King's College 🇬🇧

Ingrid Teigland Akay

Managing Partner
Hadean Ventures 🇳🇴

Cyril Teixeira Da Silva

Investment Officer
European Investment Bank 🇪🇺

Lee Wen Hwa

CEO
Action Against AMD
Director - Affordable
medicines Programme,
Oxford Martin School
University of Oxford 🇬🇧

Cheryl Zimmerlin

Principal
M Ventures 🇺🇸



HOSTED EVENT

R&D DATING FOR ANIMAL HEALTH AND INNOVATION

DECEMBER 10TH & 11TH, 2019



BioFIT 2019 will host the 5th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal health-care industry (SIMV)’s initiative, on December 10th and 11th, 2019 in Marseille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Animal health-related roundtable discussions during BioFIT:

- How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?
- Which promises to be delivered by high potential vaccines?

Organised by:




Contact: secretariat@simv.org

HOSTED EVENT

TRANSLATIONAL NEUROSCIENCE

DECEMBER 10TH, 2019



Translational Neuroscience research helps to provide R&D continuum from discovery to clinical phases by gathering multidisciplinary expertise, state-of-the-art technology platforms and innovative methodologies.

This event will highlight innovative translational research for neurodegenerative diseases with a market focus. Thus, academia-industry relationships will be developed not only from the science and technology point of view but also through training / education required to constantly remain at the forefront of innovation. This new edition will gather experts in neurodegenerative diseases and foster interactions between researchers, clinicians, biotech and pharmaceutical companies.

THE PROGRAMME IN A NUTSHELL

- 9.00 - 10.30 am Session I Translational Research Infrastructures**
DHUNE - Olivier Blin (DHUNE director)
NEURATRIS - Philippe Hantraye (MIRCen (CEA) and NeurATRIS)
Brain diseases: Advances, challenges and obstacles - Catherine Lubetzki (Pitié-Salpêtrière Hospital)
- 11.00 - 12.30 pm Round table I**
Role of public and industry actors in neuroscience translational research - What mechanisms and resources to support translation up to phase 2?
Moderator: Toni Andreu - CSO EATRIS-ERIC
Panel: Angel Cedazo-Miguez (Sanofi), Aline Jourdain (BPI), Michel Khrestchatsky (Vect-Horus), Emmanuel Le Boudier (Eurobiomed), Catherine Lubetzki (Pitié-Salpêtrière Hospital), Bruno Marroni (Protisvalor)
- 2.00 - 3.30 pm Round table II**
Stakes of training in translational neuroscience research - State-of-the-art and needs of academia and industry
Introduction of a market study on Translational neuroscience training by Vincent Gleize (Erdyn)
Moderator: François Féron - NeuroSchool Director
Panel: Olivier Blin (DHUNE), Marc Dhenain (NeurATRIS and MIRCen), Corinne Grenier (KEDGE Business School), Rosan Vegter (EATRIS-ERIC)
- 4.00 - 5.30 pm Examples of advanced translational projects**
Lionel Lamothe (Exostim), Mathieu Charveriat (Theranexus), Michel Khrestchatsky (Vect-Horus), Sylvie Claeysen (Montpellier University)

Translational Neuroscience partners:

Contact: ali.ait-ikhlef@neuratris.com



Institutional support of Roche

HOSTED EVENT

PIXR – PATIENT INNOVATION XPERIENCE BY ROCHE

DECEMBER 11TH, 2019



Roche is organising **PIXR – Patient Innovation Xperience** during BioFIT 2019. The day will be dedicated to conferences, round-tables and pitches around Health Innovation.

4 themes will be discussed:

- Access and Financing Innovation
- Data
- E-Health
- Social Innovation

Closing of the day by:

- **Mr André Comte-Sponville**, Writer, Professor, Philosopher, author of the famous “Petit traité de grandes vertus”.
- **Mr Jean-François Brochard**, President, Roche France.

Organised by:



 roche.com

HOSTED EVENT

PRECIFIT

DECEMBER 11TH, 2019



An event on **translational and collaborative research** in the field of **precision medicine** for start-ups, academic researchers, large companies, TTOs and investors.

2 highlights:

A programme of workshops

- A workshop to discuss R&D projects collaborations to answer European call for projects in precision medicine (H2020, IMI...);
- A workshop on precision medicine including examples of successful collaborations between therapeutic companies, diagnostic companies and academics.

One-to-one meetings with PreciFIT and BioFIT delegates

These one-to-one meetings with PreciFIT and BioFIT delegates aim to facilitate contacts in order to launch collaborative R&D projects, to seek funding for these projects, to seek funds for start-ups in this field of precision medicine...

Organised by:



HOSTED EVENT

EUROPEAN PROJECT IMODE

DECEMBER 10TH, 2019



IMODE is organising its fourth annual convention during BioFIT with a morning of conferences and one-to-one meetings during the afternoon.

PROGRAMME:

- 9.00 - 9.25 am **Dr Sheng Qi**, University of East Anglia
"3D printing of personalised pharmaceutical solid dosage form: promises and challenges"
- 9.25 - 9.35 am **Roxanne Khalaj**, PhD, University of Greenwich
"Fabrication of 3D printing filaments for pharmaceutical and biomedical applications"
- 9.35 - 10.00 am **Dr Steven Ross**, University of Greenwich
"Engineering of pharmaceutical cocrystals and salts: State of the art industrial approaches"
- 10.00 - 10.10 am **Luisa Roca Paixao, PhD**, University of Lille
"Carbamazepin cocrystals revisited"
- 10.10 - 10.35 am **Dr Duncan Craig**, University College London
"Nanofabrication techniques for enhanced drug delivery: from complex nanofibers to nanogels"
- 10.35 - 11.00 am **Break**
- 11.00 - 11.25 am **Dr. Youness Karrou**, University of Lille
"Hot melt extruded polysaccharide blends for controlled drug delivery"
- 11.25 - 11.35 am **Zuzana Hlaskova**, PhD, University of East Anglia
"Electrospun oral formulations for colon targeting"
- 11.35 - 12.00 pm **Natalia T. Correia**, University of Lille
"Investigation of complex molecular dynamics in multi-component systems"
- 12.00 - 12.10 pm **Jeanne-Annick Bama, PhD**, University of Lille
"Investigation of complex molecular dynamics in multi-component systems"
- 12.10 - 12.35 pm **Nicolas Descamps**, Roquette

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).

The project's overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

IMODE partners: Contact: slebrun@clubster-nsl.com project-imode.eu



The leading European partnering event
for early-stage deals and investment
rounds in the Life Sciences field

SPONSORS

GOLD SPONSORS




SILVER SPONSORS



BRONZE SPONSORS



CONTRIBUTING SPONSORS



PARTNERS

SUPPORTERS



MEDIA PARTNERS



ORGANISERS



www.eurasante.com @Eurasante

Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 30,800 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within a European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic, Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).



www.nhl-cluster.com @PoleNSL

Clubster-Nutrition Health Longevity (NHL) is a dynamic network at the intersection of health, biotechnology and nutrition. Clubster-NHL aims to connect academia and industry partners around R&D projects. It focuses on the prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.



www.biovalley-france.com @BioValleyFrance

Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation. BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory's structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow's health technologies.



www.eurobiomed.com @PoleEurobiomed

Founded in 2009 by regional stakeholders, Eurobiomed is a Life Science cluster based in Southern France. Over 285 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities are members. We lead regional initiatives and help our member businesses and research institutes to innovate, finance, develop and achieve their scientific and business objectives to ultimately improve the treatment and the lives of patients. Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centres, start-ups and industrial success stories. Among Eurobiomed's main assets are the number of people involved, the quality of the network and the mutual trust of its members, which reinforces interactions and facilitates cooperation.

JOIN BIOFIT 2019

REGISTRATION FEES

REGISTRATION FEES

Fees per person | (excl. VAT)

Mature company (> 5 years old)
Investor (pre-seed, seed or Series A)
Cluster | Association
TTO | Research institution
Emerging company (≤ 5 years old)
or SME (≤ 5 employees)
Academic scientist

	SUPER EARLY BIRD Before March 29 th , 2019 included	EARLY BIRD From March 30 th to June 28 th , 2019 included	REGULAR FEE From June 29 th to November 4 th , 2019 included	LATE REGISTRATION From November 5 th , 2019
Mature company (> 5 years old)	€ 1,032	€ 1,199	€ 1,349	€ 1,484
Investor (pre-seed, seed or Series A)	€ 1,032	€ 1,199	€ 1,349	€ 1,484
Cluster Association	€ 879	€ 1,022	€ 1,149	€ 1,264
TTO Research institution	€ 688	€ 799	€ 899	€ 999
Emerging company (≤ 5 years old) or SME (≤ 5 employees)	€ 420	€ 488	€ 549	€ 604
Academic scientist	€ 344	€ 399	€ 449	€ 494

EXHIBITION FEES

EXHIBITION FEES

(excl. VAT)

6 m² equipped stand + 1 full pass
9 m² equipped stand + 1 full pass
12 m² equipped stand + 1 full pass
18 m² equipped stand + 2 full passes

	SUPER EARLY BIRD Before March 29 th , 2019 included	EARLY BIRD From March 30 th to June 28 th , 2019 included	REGULAR FEE From June 29 th to November 4 th , 2019 included
6 m ² equipped stand + 1 full pass	€ 2,200	€ 2,400	€ 2,600
9 m ² equipped stand + 1 full pass	€ 3,300	€ 3,500	€ 3,700
12 m ² equipped stand + 1 full pass	€ 4,400	€ 4,600	€ 4,800
18 m ² equipped stand + 2 full passes	€ 6,600	€ 6,800	€ 7,000

SPONSORSHIP PACKAGES



Platinum Sponsor
€ 20,000



Gold Sponsor
€ 15,500



Silver Sponsor
€ 11,000



Bronze Sponsor
€ 6,500

Please contact us for other sponsorship opportunities.



Marseille

One of the best innovative hubs for biotech in Europe

The Aix-Marseille-Provence Metropolis and the Sud Provence-Alpes-Côte d'Azur Region are a dynamic hotbed for biotech and pharma innovations, providing unrivalled assets and cutting edge resources. This is due in particular to its leading research and training centres, its incubators which boost R&D projects, Eurobiomed, the cluster which supports innovations' development all along their development and its dedicated network including clusters, industries, SMEs and start-ups.

Event Venue

PARC CHANOT
114, Rond-Point du Prado
13008 Marseille, France

General Enquiries

Margaux Satola
msatola@eurasanté.com
+33 (0)3 59 39 01 82

Conference Programme

Claire Lesnik
clesnik@eurasanté.com
+33 (0)3 59 39 01 87

Organisers:



Institutional Partners:

